Jazz Pharmaceuticals
Jazz Pharmaceuticals plc
3170 Porter Drive
Palo Alto, CA 94304
Phone: (650) 496 3777Website: https://www.jazzpharma.com/Careers: careers.jazzpharma.com
Latest news
- FDA Grants Accelerated Approval to Modeyso (dordaviprone) for the Treatment of Recurrent H3 K27M-Mutant Diffuse Midline Glioma
6 August 2025 - Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma
18 February 2025 - Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
30 December 2024 - Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
9 December 2024 - FDA Grants Accelerated Approval to Ziihera (zanidatamab-hrii) for the Treatment of HER2-Positive Biliary Tract Cancer
20 November 2024 - Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
16 September 2024 - Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer
1 June 2024 - Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
29 May 2024 - Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
2 April 2024 - Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
2 June 2023
Drugs Associated with Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc manufactures, markets and/or distributes more than 8 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Defitelio
Generic name: defibrotide Drug class: miscellaneous coagulation modifiers |
||
|
Epidiolex
Generic name: cannabidiol Drug class: miscellaneous anticonvulsants |
3 reviews | 5.2 / 10 |
|
Rylaze
Generic name: asparaginase erwinia chrysanthemi Drug class: miscellaneous antineoplastics |
||
|
Vyxeos
Generic name: cytarabine liposomal/daunorubicin liposomal Drug class: antineoplastic combinations |
||
|
Xyrem
Generic name: sodium oxybate Drug class: miscellaneous anxiolytics, sedatives and hypnotics |
108 reviews | 7.6 / 10 |
|
Xywav
Generic name: calcium oxybate/magnesium oxybate/potassium oxybate/sodium oxybate Drug class: miscellaneous anxiolytics, sedatives and hypnotics |
16 reviews | 8.2 / 10 |
|
Zepzelca
Generic name: lurbinectedin Drug class: alkylating agents |
||
|
Ziihera
Generic name: zanidatamab Drug class: HER2 inhibitors |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
Discontinued Drugs
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
FazaClo
Generic name: clozapine Drug class: atypical antipsychotics |
||
|
Luvox CR
Generic name: fluvoxamine Drug class: selective serotonin reuptake inhibitors |
12 reviews | 7.2 / 10 |
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||